Bietti crystalline dystrophy
Zuletzt aktualisiert 18. Aug 2020
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Bietti crystalline dystrophy is a disorder in which numerous small, yellow or white crystal-like deposits of fatty (lipid) compounds accumulate in the light-sensitive tissue that lines the back of the eye (the retina). The deposits damage the retina, resulting in progressive vision loss.
Videoauswahl für Genetische ErkrankungenVideothek
Beschreibung
Bietti crystalline dystrophy is a disorder in which numerous small, yellow or white crystal-like deposits of fatty (lipid) compounds accumulate in the light-sensitive tissue that lines the back of the eye (the retina). The deposits damage the retina, resulting in progressive vision loss.
People with Bietti crystalline dystrophy typically begin noticing vision problems in their teens or twenties. They experience a loss of sharp vision (reduction in visual acuity) and difficulty seeing in dim light (night blindness). They usually lose areas of vision (visual field loss), most often side (peripheral) vision. Colour vision may also be impaired.
The vision problems may worsen at different rates in each eye, and the severity and progression of symptoms varies widely among affected individuals, even within the same family. However, most people with this condition become legally blind by their forties or fifties. Most affected individuals retain some degree of vision, usually in the center of the visual field, although it is typically blurry and cannot be corrected by glasses or contact lenses. Vision impairment that cannot be improved with corrective lenses is called low vision.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Other names
BCD
Bietti crystalline corneoretinal dystrophy
Bietti crystalline retinopathy
Bietti tapetoretinal degeneration with marginal corneal dystrophy
Related patient information and medicines

Patient information leaflet
Muskelschwäche
This leaflet looks at types of Muskelschwäche and discusses the wide range of problems which can cause them. Some of these causes are very common and others are very rare. Some are mild and reversible; others are not. Most can be improved by exercise and physiotherapy. Muscle weakness is a common complaint but the word weakness can mean different.

Patient information leaflet
Genetische Tests
What is genetic testing. Genetic testing is a type of medical test that identifies changes in chromosomes, genes or proteins. Gene tests look for abnormalities in DNA taken from a person's blood, body fluids or tissues. Fluorescent in situ hybridisation (FISH) analysis - this test looks at certain parts of the chromosomes and can detect very small.

Patient information leaflet
Amniozentese
Was ist amniocentesis. Amniocentesis is a procedure that is carried out during pregnancy Pregnancy screening tests. It involves taking a sample of the fluid inside your womb (uterus) that surrounds your developing baby. Amniocentesis is a diagnostic test. In most cases it tells you for certain whether or not your baby has a... Examples include.

Patient information leaflet
Metatarsalgie
Metatarsalgie is the name given to Schmerzen in the front part of the foot under the heads of the metatarsal bones, also known as the ball of the foot. Metatarsalgia can be caused by a numb... Pes cavus can run in families but it can also happen out of the blue. Most people with pes cavus also have a neurological problem such as cerebral palsy, spina.

Patient information leaflet
Chorionzottenbiopsie
Chorionzottenbiopsie (CVS) is a procedure that is carried out during Schwangerschaft to diagnose or exclude various chromosomal or genetic conditions in your unborn developing baby. A very small sample of tissue is taken... A screening test for Down's syndrome Down's syndrome screening is offered to all schwangere women in the UK. Examples include.

Patient information leaflet
Sehprobleme
Most types of RP become apparent between the ages of 10 and 30. There is currently no treatment which stops the progress of the condition, although complete loss of vision is uncommon. Retinal dystrophy Retinal dystrophies are a group of inherited (genetic) disorders which result in changes to the retina which may affect vision. They are fairly.
Weiterführende Lektüre und Referenzen
- Bietti crystalline dystrophy; MedlinePlus, National Library of Medicine.
- Li A, Jiao X, Munier FL, Schorderet DF, Yao W, Iwata F, Hayakawa M, Kanai A, Shy Chen M, Alan Lewis R, Heckenlively J, Weleber RG, Traboulsi EI, Zhang Q, Xiao X, Kaiser-Kupfer M, Sergeev YV, Hejtmancik JF. Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. Am J Hum Genet. 2004 May;74(5):817-26. doi: 10.1086/383228. Epub 2004 Mar 23.
- Mamatha G, Umashankar V, Kasinathan N, Krishnan T, Sathyabaarathi R, Karthiyayini T, Amali J, Rao C, Madhavan J. Molecular screening of the CYP4V2 gene in Bietti crystalline dystrophy that is associated with choroidal neovascularization. Mol Vis. 2011;17:1970-7. Epub 2011 Jul 20.
- Mansour AM, Uwaydat SH, Chan CC. Long-term follow-up in Bietti crystalline dystrophy. Eur J Ophthalmol. 2007 Jul-Aug;17(4):680-2. doi: 10.1177/112067210701700434.
- Rossi S, Testa F, Li A, Iorio VD, Zhang J, Gesualdo C, Corte MD, Chan CC, Fielding Hejtmancik J, Simonelli F. An atypical form of Bietti crystalline dystrophy. Ophthalmic Genet. 2011 Jun;32(2):118-21. doi: 10.3109/13816810.2011.559653. Epub 2011 Mar 8.
- Xiao X, Mai G, Li S, Guo X, Zhang Q. Identification of CYP4V2 mutation in 21 families and overview of mutation spectrum in Bietti crystalline corneoretinal dystrophy. Biochem Biophys Res Commun. 2011 Jun 3;409(2):181-6. doi: 10.1016/j.bbrc.2011.04.112. Epub 2011 May 1.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
18. Aug 2020 | Neueste Version
1 Nov 2012 | Ursprünglich veröffentlicht
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

